Throne Biotechnologies Email Formats

About Throne Biotechnologies

Throne Biotechnologies (Throne) is a clinical-stage therapeutic company with a disruptive stem cell technology that can fundamentally reverse type 1 diabetes (T1D), alopecia areata (AA) and other autoimmune diseases through immune education of Stem Cell Educator therapy (“Educator Therapy”) at the root causes. Over last 10 years, international multicenter clinical trials in Spain, China, and the United States have strongly demonstrated the clinical safety and efficacy of Educator therapy in more than 200 patients aged from 3 to 70 years old. Currently, Throne has received three FDA-approved phase 2 INDs by using Educator therapy to treat T1D, AA, and severe COVID-19 patients. Specifically, our globally-patented technology is recognized as the leading “Practical Cure Project” for T1D out of 590 global projects (Juvenile Diabetes Cure Alliance (JDCA) 2021, New York). T1D is a T cell–mediated autoimmune disease that causes a deficit of islet beta cells. Millions of individuals worldwide have T1D, and incidence increases markedly since COVID-19 pandemic started. Recent clinical trials have highlighted the limits of conventional immune therapy and underscore the need for novel approaches that not only overcome multiple immune dysfunctions, but also help restore islet beta-cell function. To address these two key issues, Throne has developed a unique and novel Educator therapy by using a new type of cord blood-derived multipotent stem cells (CB-SC). With this patented technology, a patient’s blood is circulated through a blood cell separator, where the patient’s immune cells are co-cultured with adherent CB-SC in vitro, and returns “educated” immune cells to the patient’s circulation. Notably, Educator therapy is the only therapy to date to safely and efficiently correct autoimmunity and restore beta-cell function in T1D patients.

View contact profiles from Throne Biotechnologies